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INTRODUCTION 
 
“Fighting the fear in pregnancy – BP” 
Is still a mystery 
Cause is obscure 
 
 Preeclampsia is a multi system disorder which affects the vascular 
system and manifests by hypertension and proteinuria after 20weeks of 
gestation and returns to normal by 12 weeks in the postnatal period. 
 Every day, 830 women die due to Pregnancy associated disease 
and childbirth.  
WHO estimates maternal death about 216. 
Most of the death occurs in the developing Countries about 98-
99%.Preeclampsia and eclampsia is main contributable and preventable 
cause of maternal death. Maternal mortality which is higher in rural 
areas and among poorer communities. Now trend is changing, it also 
occurs in urban population. 
 Clear protocols for early detection and managing the 
hypertension in pregnancy in all levels of health care by skilled 
personnel before, during and after childbirth are needed for good 
maternal and neonatal outcome. Between year 1990 and 2015, maternal 
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mortality worldwide declined about 44%.This translates into an average 
annual rate of reduction of 2.3 percent. According to the Sustainable 
Development Goals, global maternal mortality ratio has to be reduced by 
2016-2030 to a level less than 70% in 1,00,000 live births. 
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CAUSES OF MATERNAL DEATH WORLDWIDE  
● Obstetric haemorrhage 25% 
● Infection 15% 
● Unsafe abortion 13% 
● Hypertensive disorders of pregnancy 12% 
● Obstructed labour 8% 
● Other direct causes 8% 
● Indirect causes 20% 
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EPIDEMIOLOGY 
      Preeclampsia is a significant public health threat in both developed 
and developing countries contributing to maternal and perinatal 
morbidity and mortality globally. India’s third National Family Health 
Survey says factors responsible for the prevalence of preeclampsia that 
are socio-demographic, maternal, lifestyle and dietary determinants. The 
incidence of preeclampsia is reported to be 8-10% in India. The 
prevalence of hypertensive disorders of pregnancy was 7.8% of with 
preeclampsia. The recent World Bank data says MMR for India reported 
in 2015 at 174 per 100,000 live birth, which is declined from215reported 
in 2010 
 
 
 
 
 
 
 
 
 
 
10 
 
 
AIMS OF STUDY 
• My study is about whether prolactin has a role in pathogenesis of 
preeclampsia and its severity, whether it can be used as a predictor 
of preeclampsia . 
• STUDY DESIGN-PROSPECTIVE STUDY. 
 
OBJECTIVES 
•  To find if prolactin has a role in pathogenesis of preeclampsia. 
• To compare serum prolactin level  in all preeclampsia patients with 
normal healthy pregnant women 
• To correlate serum prolactin levels with severity of preeclampsia 
and its outcome.  
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REVIEW OF LITERATURE 
 
Timalsina et al  did a case control study of which54 cases and 60 
controls. The median level of Prolactin was significantly higher in pre 
eclamptic women when compared to normal pregnant women according to 
this study. 
Alfredo ullareo et al conducted a studied the relationship between 
the serum and urinary prolactin levels among preeclamptic women and 
also excretion of antiangiogenic prolactin fragments in urine. According to 
his study the level of urinary prolactin excretion was significantly higher 
among hypertensive patients. 
 Alfredo Leaños-Miranda et al., conducted a randomised study of 
Circulating Factors and serum Prolactin  level.  They are used as Predictors 
in Women With Preeclampsia, to deal about the adverse outcomes. They 
assessed whether these biomarkers are involved in the adverse maternal 
and perinatal outcomes in preeclamptic women. They conducted study in 
501 women with preeclampsia who attended the tertiary care hospital. 
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THEORIES OF PREECLAMPSIA 
21
ST
 CENTURY RECENT THEORY 0F DISEASE CAUSATION. 
At present many theories are suggested to explain etiogenesis, some are; 
1. IMMUNOGENIC INTOLERANCE THEORY: 
● Intolerance between fetoplacental unit and maternal tissue. 
● Put forth by Leeman and Fontaine in 2008 
 
2. TWO STAGE MODEL PREECLAMPSIA: 
● Proposed by Roberts and Hubel in 2009. 
● STAGE 1: abnormal location of placenta and subsequent 
remodeling leads to placental hypoperfusion causing maternal 
syndrome. 
● STAGE 2:Occlusivemicro thrombi affecting multiple organs, 
leads on to hypertension, proteinuria and Oedema. 
This is the pathognomonic feature of preeclampsia. 
3. PLACENTAL TOXINS (cytokines, angiogenic factors, VEGF, 
free placental growth factors etc) are not tolerated by some women 
leading to preeclampsia. 
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AETIO PATHOGENESIS OF PRE ECLAMPSIA 
 The main characteristic feature of preeclampsia is abnormal 
trophoblastic invasion of uterine vessels, in appropriate endothelial 
activation, exaggerated inflammatory response, maladaptation to 
cardiovascular changes of normal pregnancy.  
 
It is hypothesized as two stage disorder 
PRIMARY STAGE- 
Defective Physiological changes 
 
Incomplete Trophoblastic invasion of the myometrial part of spiral arteries 
 
Vasospasm 
 
                       Uteroplacental Hypoperfusion 
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SECONDARY STAGE  
ABNORMAL IMMUNE RESPONSE BY ENDOTHELIAL 
ACTIVATION 
 There is release of toxins into maternal circulation due to the 
placental hypoxia which is later followed by reperfusion at that site, this 
released toxins leads to many inflammatory reactions in the body of the 
patient , leads onto exagarrated immune response which leads onto signs 
and symptoms suggestive of multi organ failure. 
 
ACTIVATION OF THE VASCULAR ENDOTHELIUM 
 Placental factors like VEGF, free placental growth factors leading to 
oxidative stress, activation of leucocytes, formation of free radicals and 
lipid peroxides. This causes activation of nitric synthetase enzyme in 
endothelium that leads to increased vascular permeability and edema. 
 
ANGIOGENIC FACTORS 
Imbalance between angiogenic and anti angiogenic substance 
associated with severity of disease. Some are;soluble fms like tyrosine 
receptors, free placental like growth factors, angiotension etc. 
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GENETIC FACTORS 
 Some genes have possible associations with preeclampsia syndrome 
like genes involved in FactorV, Angiotensinogen, Methylene 
tetrahydrofolate reductase, Human leukocyte antigens, Lipoprotein lipase, 
decreased methylation. 
EXAGGERATED PRESSOR RESPONSE 
 Preelamptic patients, when exposed to substances like angiotensin2, 
deoxycortisone and nor epinephrine, have an exaggerated vascular 
response. 
NITRIC OXIDE 
 It is a potent vasodilator, synthesized from L-ariginie. It is secreted 
by endothelium. In preeclampsia, there is decreased endothelial nitric 
oxide synthesis which leads to diffuse vasospasm. 
PROSTOGLANDINS 
 The prostanoids  have important  role in the pathogenesis of pre 
eclampsia. In NORMAL PREGNANCY the decreased response to pressor 
agents due to production of prostacyclin. 
In PREECLAMPSIA- there is less  production of   PGI2 and there is 
more production of thrombaxne A2 from the platelet . Alteration in 
prostacyclin to thromboxane A2  ratio leads to increased sensitivity to 
these substances. 
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DIAGNOSIS OF HYPERTENSION: 
  Defined as systolic BP>140mm Hg and diastolic BP >90mm Hg on 
two occasions at least 6 hours apart ,taken in the same arm. 
 Instead of relaying single high value ,average value of BP for a 
week or high BP during booking visit or preconceptional visit  has 
increased risk or maternal and perinatal outcome. 
 
Measurement of blood pressure 
● In sitting posture with arm at the level of heart. 
● Appropriate cuff size to be used (length of 1.5 times the 
circumference of arm) 
● Korottoff phaseV is taken as diastolic BP 
● .If diastolic BP less than 40mmHg, then phase IV is taken  
 
Measurement of Proteinuria: 
  Urinary dipstick testing (automated reagent strip)reading device is 
recommended.It may be used for screening the patients for proteinuria  It 
has many advantages like  easy availability, rapid and low cost, so can be 
used in all most all pregnant women who are at risk of developing pre 
eclampsia. 
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Grading for proteinuria is 
TRACE  - 0.1mg/dl 
1+            -  .3mg/dl 
2+            - 1mg/dl 
3+            - 3mgdl 
4+           -  10mg/dl 
 The automated reagent strips is recommended to reduce 
interobserver variations and to reduce false positivity. 
 
What is Clinically Significant Proteinuria: 
 Urinary excretion of 300mg or more of protein in 24 hours urine 
collection or persistent 30mg/dl in random clean catch sample on atleast 2 
occasions collected 6 hours apart. 
This corresponds to protein /creatinine to 30nmol. 
This is clinically Significant Proteinuria. 
 
URINE SPOT PCR 
   This is an alternative and rapid method for 24 hours urine protein, spot 
protein to creatinine ratio of more than 0.3 denotes significant proteinuria . 
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DIFFERENT TYPES OF CLASSIFICATION OF PREGNANCY 
National High Blood Pressure Education Program (NHBPEP) 
Working Group, the classification is as follows
 
: 
 
• Gestational hypertension 
● Chronic hypertension 
● Preeclampsia 
● Eclampsia 
● Super imposed preeclampsia (on chronic hypertension) 
Gestational hypertension: 
The characteristics  to diagnose a patient as gestational hypertension 
is by the recording the BP of 140/90 mm Hg or more for the first time after 
20 weeks of gestation measured on two occasions. And also the Blood 
pressure  returns to normal in less than 12 weeks' postpartum 
 
Chronic hypertension: 
Chronic Hypertension is the one  which is diagnosed  before 20 
weeks of gestation and also  which remains persistent after 12 weeks of 
post partum period. Before labeling some one as chronic hypertension, 
Molar pregnancy and other secondary cause of hypertension has to be 
ruled out. 
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DEFINITION FOR PREECLAMPSIA 
It is defined as BP>140/90  with proteinuria more than *1 and who have 
protein in 24 hr urine collection >0.3g beyond 20 weeks of gestation. 
 
SUPERIMPOSED PREECLAMPSIA: 
 Criteria for superimposed preeclampsia; 
(1)  Known case of hypertension with a New onset proteinuria (≥300 
mg/24 h)  
(2) A sudden increase in proteinuria or blood pressure or thrombocytopenia 
less than 100,000/mm
3
or renal changes(elevated creatinine level)in a 
woman with hypertension  and proteinuria before 20 weeks of 
gestation. 
ECLAMPSIA. 
It is the Severe form of pre eclampsia. 
Literally means “flash of lights”. 
It is clinically characterized by sudden onset of generalized tonic and 
clonic form of seizures during pregnancy or childbirth. 
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National Institute for Health and Care Excellence (NICE, UK: 
CLASSIFICATION OF HYPERTENSION 
● Mild: systolic BP 140 to 149mmHg and /or  diastolic BP  90 to 
99mmHg 
● Moderate: : systolic BP 150 to 159mmhg and /or  diastolic BP>  100 
to 109 mmHg 
● Severe: : systolic BP >160mm/hg and /or  diastolic BP  >110mm/hg 
 
AMERICAN CONGRESS OF OBSTETRICIANS AND 
GYNECOLOGISTS (ACOG)  
INDICATORS OF SEVERITY OF GESTATIONAL HYPERTENSIVE 
DISORDERS 
 Non severe 
 Severe 
ABNORMALITY NONSEVERE SEVERE 
● DIASTOLIC BP 
 
● SYSTOLICBP 
 
● PROTEINURIA 
 
● HEADACHE 
 
● VISUAL 
DISTURBANCES 
 
<110 mmHg 
 
<160 mm Hg 
 
None to positive 
 
Absent 
 
 
Absent 
 
≥ 110mmHg 
 
≥ 160 mm Hg 
 
None topositive 
 
Present 
 
 
Present 
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● EPIGASTRIC PAIN 
 
● OLIGURIA 
 
● SERUM CREATININE 
 
● THROMBO 
-CYTOPENIA 
 
● SERUM 
TRANSAMINASE 
ELEVATION 
 
● FGR 
 
● PULMONARY EDEMA 
 
● GESTATIONAL AGE 
 
           Absent 
 
Absent 
 
Normal 
 
 
Absent 
 
 
Minimal 
 
 
Absent 
 
           Absent 
 
Late 
Present 
 
Present 
 
Elevated 
 
 
Present 
 
Marked 
 
 
           Present 
 
           Present 
 
Early 
 
RISK FACTORS 
Risk factors for pre-eclampsia include more and complexity of the 
disease. . These can be classified based on familial factors, demographic 
factors, past medical or obstetric history, pregnancy-associated factors, 
paternal factors and miscellaneous factors. The placenta plays a vital  
role in the pathogenesis of pre-eclampsia, thus implying that both 
maternally and paternally derived fetal genes may play a role in the 
development of the disease . 
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Demographic factors 
Age 
Extremes of maternal age is an important factor. Maternal age more 
than 35 years has more  risk for preeclampsia though not for eclampsia. 
However, women less than19 years of age were at high risk for eclampsia, 
but not a diagnosis of pre-eclampsia. This may be due to under diagnosis 
of preeclampsia and inadequate antenatal care. 
Ethnicity 
South Asian and African population have higher incidence of 
preeclampsia, while American women more prone for HELLP 
(haemolysis, elevated liver enzymes and low platelet) syndrome. 
 
Stature and pre-pregnancy body mass index 
  Short stature  women of 145 cm are predisposed to have  increased 
risk of severe preeclampsia 
Women who are overweight or obese are known to have increased 
risk for preeclampsia due to maternal adiposity. BMI 21 to 30 kg/m2 have 
greater risk of developing preeclampsia. 
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Pre-existing medical conditions 
Pre-gestational diabetes (type 1 and type 2) is an important contributor of 
new onset of preeclampsia. Women with chronic hypertension were at risk 
of getting superimposed preeclampsia. Preeclampsia chances are more 
with chronic kidney disease, lupus nephropathy, as well as diabetic 
nephropathy. Especially women with diabetes, proteinuria of either190–
of preeclampsia. High levels of total cholesterol and low levels of High 
density lipoprotein level has associating factor for preeclampsia. 
 
THROMBOPHILIA 
Testing for inherited thrombophilias (such as factor V Leidenmutation, 
prothrombin gene mutation, protein C or S deficiency, or antithrombin III 
deficiency) or acquired thrombophilia (such antiphospholipid antibodies) 
are very important. Factor V Leiden was more   significant. The 
antiphospholipid syndrome (APS) is a systemic autoimmune disorder 
which  is characterized by arterial and venous thrombosis, has poor 
pregnancy outcomes. Routine screening is not recommended. 
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Parity 
Preeclampsia is recognised to more commonly complicate   first pregnancy 
and increases the risk of late-onset pre-eclampsia when compared with 
early-onset disease. 
 
Interval between pregnancies 
The risk of pre-eclampsia is generally lower in the second pregnancy .Birth 
interval more than 4years with no prior history of preeclampsia have 
higher risk. 
 
previous miscarriages 
women who had recurrent spontaneous abortions and infertilitytreatment, a 
three-fold increased risk of pre-eclampsia 
 
previous pre-eclampsia 
The risk of recurrent pre-eclampsia was 12% for those who previously 
delivered at term and increased to 40% for those who delivered before 28 
weeks of gestation. 
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Pregnancy-associated factors 
Multiple pregnancy 
Twin pregnancy had higher rates of gestational hypertension and pre-
eclampsia due to increased placental mass. This leads to  increased 
circulating levels of soluble fms-like tyrosinekinase-1 (sFlt1), which is a 
circulating antiangiogenic marker of placental origin, and may play an 
important role in pathophysiology of, especially early-onset of pre-
eclampsia. 
Fetal gender 
Male gender have preponderance to preeclampsia than that of 
females.  
Infections 
Women with UTI and periodontal disease are more likely to develop 
pre-eclampsia. There was  some association between the other maternal 
infections like chlamydia, malaria, treated or untreated HIV and group B 
streptococcal colonisation and risk of pre-eclampsia are noted 
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Paternal factors 
Paternal age 
Epidemiological studies shows  that the risk for pre-eclampsia 
increases in the woman has a partner aged>45 years, because spermatozoa 
had genetic mutation due to ageing or environmental factors such 
as exposure to radiation and heat. 
 
Primipaternity and sperm exposure 
Increased risk of preeclampsia if women conceives within 4 months 
or less. This risk decline every month delay in conception. Repeated 
intercourse with the same partner leads to maternal mucosal tolerance to 
paternal antigens, which maybe mediated by seminal vesicle-derived 
transforming growth factor. This is not a significant factor. 
 
Paternal medical history 
Higher lipid profile, myocardial infarction and high BMI are some 
additive factors. 
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MISCELLANEOUS FACTORS 
SMOKING 
Cigarette smoking is known to have adverse effects on all organ 
systems. But smoking decrease the risk.This is protective effect was not 
well established. But smoking have effects on angiogenicfactors, 
endothelial function and the immune system, which may contribute to the 
lowered risk of pre-eclampsia. 
 
physical activity 
Exercise and physical activity is advised during pregnancy to improve 
maternal health. These people less likely to develop preeclampsia 
 
micronutrient deficiencies 
Vitamin D deficiency is associated with pre-eclampsia. Level of 
vitamin D <30 nmol/L, was associated with the risk of pre-eclampsia 
 
Mental health 
Depression and anxiety in the first trimester of pregnancy are found 
to increase the risk of pre-eclampsia . Any lifetime stress and perceived 
stress during pregnancy may cause pre-eclampsia. It may be mediated by 
the neuropsychoimmunological pathway. 
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Socioeconomic status 
In developing countries, rural people were more likely to get pre-
eclampsia when  compared with urban people. Furthermore, women with 
concurrent anemia and poor intake of fruits and vegetables were at higher 
risk of pre-eclampsia. 
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MATERNAL CHANGES OF PRE ECLAMPSIA 
HEART CHANGES 
NONSEVERE PREECLAMPSIA 
  This would mainly increase the cardiac output rather than increase in 
peripheral vascular resistance 
SEVEREPREECLAMPSIA- 
There is decrease in cardiac output and elevated peripheral vascular 
resistance which leads to rise in BP.  
This result in traumatic  intravascular haemolysis (microangiopathic 
haemolytic anemia ) 
 
WATER AND ELECTROLYTES CHANGES 
Relative hypovolemia  in preeclampsia causes  depletion of 
intracellular space. The fluid shift into extracellular space leads to edema. 
Proteinuria in these women creates reduced oncotic pressure and further 
causes fluid shift. 
Thus hypovolemia can be identified by hemo concentration, which 
in turn may affect the birth weight of the baby and also lead on to perinatal 
mortality and prematurity in the babies born to them. 
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PHYSIOLOGICAL EDEMA 
In pregnancy is due to raised intracapillary hydrostatic pressure. 
PATHOLOGICAL OEDEMA 
It is mainly due to 
● increased permeability to plasma proteins  
● reduction in plasma colloid oncotic pressure. 
 
SIGNS AND SYMPTOMS OF EDEMA 
● Sudden appearance of pathological  swelling around periorbital 
regions and in the  face. 
● Rapid increase in the  weight>1kg/week for 2 – 3 weeks or >2 
kg/week in 1 week, mainly in last trimester 
 
INTRAVASCULAR VOLUME CHANGES  
HEMOCONCENTRATION 
This is the main hallmark of severe preeclampsia and eclampsia. 
 The physiological expansion of blood volume in normal pregnancy is 
about 4500ml. 
          This is mainly by 40% increase in plasma volume, blood volume in a 
normal person is only about 3000ml. 
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The generalized vasospasm and leakage of plasma  proteins into interstitial 
space in case of pre eclampsia leads to loss of this extra 1500ml of blood. 
After delivery, vasoconstriction reverses, blood volume reexpands, causes 
fall in the hematocrit and hemoglobin, so even small blood loss during 
delivery should be managed carefully. The Preeclamptic patient have 
increased sensitivity to both fluid therapy and blood loss . 
 
CHANGES IN PERIPHERAL VASCULAR RESISTANCE: 
Normotensive women during pregnancy show  resistance to pressor 
agent ANGIOTENSIN II AND CATECHOLAMINE throughout gestation, 
in contrast preeclampsia. 
HEMATOLOGICAL  CHANGES 
 MILD THROMBOCYTOPENIA (7% - 10% of cases).is the most 
common abnormality . 
 OVERT THROBOCYTOPENIA i.e. platelet count  <1,00,000/ϻl- 
severity of disease 
 In most cases, the platelet count continues to decrease first day of 
delivery then it reaches normal level by 3-5 days postpartum in 90% cases 
and it does not affect the neonatal platelet count. 
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COAGULATION CHANGES 
1. There is found to be a decrease in the level of clotting factor, factor 
viii. 
2. Pre eclamptic patients also shows an Increases fibrinogen levels and 
D-dimers. 
3. Reduced level of antithrombinIII, proteinC and proteins. 
But investigations like partial and activated thromboplastin time are not 
routinely required, can be used only in case of abruption placenta. 
 
CEREBRAL CHANGES 
Acute and severe hypertension 
1
ST
-Overregulation of cerebral perfusion 
Vasospasm-cytotoxic edema 
2
nd
-forced vasodilation and vasoconstriction  
High hydrostatic pressure, hyperperfusion 
Vasogenic edema 
Loss of autoregulation-eclamptic seizures. 
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SIGNS AND SYMPTOMS: 
● Hyperreflexia and clonus 
● Eclamptic seizures are found to be grand mal in nature. 
● Frontal headache - It is due to vasospasm of frontal cortex  
It is not relieved by analgesics. 
 Visual disturbances and cortical blindness can also occur 
PRES. (POSTERIOR REVERSIBLE ENCEPHALOPATHY 
SYNDROME) – 
Constriction in visual field of the cortex. Maternal mortality is most 
commonly found to be due to cerebrovascular accidents. 
 
RENAL CHANGES: 
 In normal pregnancy , it is very well known that there is increase in 
the Renal perfusion and glomerular filtration rate, Lets see the changes in 
the pre eclamptic patients. 
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In preeclampsia: 
resistance in renal afferent arterioles increased 
 
renal hypoperfusion 
 
reduced glomerular filtration rate 
 
PATHOLOGY: 
  It is characterized by swollen glomerular intracapillary endothelial 
cells and  called as GLOMERULAR ENDOTHELIOSIS. 
 
ELECTRON MICROSCOPY 
 Shows deposition of osmophilic material in the cytoplasm of 
endothelial cell. This is reacted with antibodies against fibrinogen and 
fibrin seen in immunoflourescence. 
 
Preeclamptic patients have high level of uric acid and  they also 
show diminished excretion of urinary calcium, which is mainly due to 
altered GFR in these patients. 
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Glomerular Endotheliosis 
 
 Swollen endothelial cells in pre eclamptic patients is leading on to 
partial obstruction in many of the capillary lumens this is indicated in the 
figure by large arrows. Mitosis indicates cellular repair taking place in the 
preeclamptic patients, which is shown by small arrow. 
  Acute renal azotemia is a rare in these patients. 
 
COMPLICATIONS OF PRE ECLAMPSIA 
 Most common is acute tubular necrosis This is mainly due to 
bilateral cortical necrosis. 
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LIVER  CHANGES: 
hepatic sinusoids shows fibrin deposition  
hypoperfusion to liver 
vasospasm mediated hypoxemia 
liver enzymes released into circulation 
 
● subcapsularedema and stretching 
● Hepatocellular necrosis 
● Periportalhaemorrhages 
● Sub capsular hematoma 
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HELLP SYNDROME: 
This is the most serious complications of preeclampsia, which is 
characterized by: 
● Haemolysis 
● Elevated Liver enzymes 
● Low Platelets count 
 
PATHOGENESIS: 
 Due to endothelial disruption with platelet adherence and fibrin 
deposit leads to micro angiopathic haemolysis. 
The HELLP syndrome precedes to consumptive coagulopathy and 
DIC. 
HEMOLYTIC ANEMIA: 
Hemolysis  is diagnosed by: 
● IN SERUM: elevated lactate dehydrogenise and low haptoglobin 
level. 
● IN PERIPHERAL SMEAR:will showschizocytosis, spherocytosis 
and reticulocytosis 
 
 
 
40 
DIAGNOSIS: 
1.Confirmation of hemolysis by elevated LDH or peripheral smear 
findings. 
1. AST or ALT >70 IU/L. 
2. Platelet count  below 100000 /ϻl 
 
UTERUS AND PLACENTAL CHANGES 
 The major cause of perinatal morbidity and mortality was 
diminished uteroplacental perfusion. 
 Resistance was more pronounced in peripheral vessals than 
central-a”ring like “distribution. 
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               SCREENING TEST FOR PRE ECLAMPSIA 
Various biochemical and biophysical markers are  proposed for its 
prediction of preeclampsia but there is no reliable valid and economical 
screening test available  
 
TEST FOR VASCULAR /PLACENTAL PERFUSION 
RESISTANCE; 
MID TRIMESTER BLOOD PRESSURE 
 Normal drop in mid trimester blood pressure has been not noted in  
preclampsia . 
 If mean Arterial pressure > 90 mmHg  is more risk  of developing 
pre eclampsia. 
HAND GRIP TEST . 
 Rise of diastolic pressure of greater than 20mmHg during this test at 
28 to 32 weeks of gestation had a positive predictive value of 20 to 30%. 
ANGIOTENSION II INFUSION TEST 
 The level of Angiotension II less than 8ng/dl minute to increase BP  
by  20mm Hg has a positive predictive value of 20to 40% for developing 
pre eclampsia. 
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ROLL OVER TEST 
 A test in which blood pressure is recorded in left lateral position. 
Then she rolls into the supine position and  blood pressure is noted after 5 
minutes  .If the  Diastolic BP raised to more than 20mmHg  had a more 
positive predictive value of 33%. 
DOPPLER  STUDY 
 Uterine Artery impedence around 18 weeks is an early second 
trimester  screening test.  
 
TESTS FOR KIDNEY DYSFUNCTION: 
URIC ACID 
 Level greater than 5.9 mg/dl had a positive predictive value of 33%. 
CALCIUM METABOLISM. 
 if the level of 24  hour urinary calcium level was less than 12 mg/dl 
has positive value of about 91%. 
URINARY KALLIKREIN EXCRETION  
 Diminished excretion and  reduced level of Kallikrien which  is an 
essential pressor agent is a predictor of pre eclampsia. 
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TESTS FOR ENDOTHELIAL DYSFUNCTION: 
FIBRONECTIN 
 Greater than 400ng/dl of fibronectin level is important to develop 
preeclampsia. 
PLACENTAL PEPTIDES  
 InhibinA, ActivinA, PAPP-A, Placental protein13 are early markers 
of preelampsia which are trial. 
 
PROLACTIN AS A PREDICTOR OF PRE ECLAMPSIA 
 My aim of study is about whether prolactin can be used a predictor 
of pre eclampsia and whether it has an importance in the pathogenesis. 
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PROLACTIN 
 Prolactin (PRL), otherwise known as luteotropin, is a polypeptide  
protein, which has vital  role in milk secretion,especially in female 
mammals. Prolactin is synthesized from anterior  pituitary gland  by 
lactotrophs. 
         The main stimulus for prolactin secretion  is found to be during many 
of our normal activities like eating, mating , stress  and ovulation, also 
during estrogen treatment and during nursing. 
  
 Prolactin is found to be secreted in pulsatile manner.. It also has an 
important role in the regulation of the immune system. The main function 
of prolactin  in human is in  milk production. It may also act  as a growth 
factor and angiogenic factor. It acts binding to cytokine-like receptors , 
through which it plays a vital role in hematopoiesis, angiogenesis and is 
also involved in the regulation of blood clotting pathways.  
The hormone acts as both in autocrine and in a paracrine  manner 
through  its  prolactin receptor and a cytokine receptors. 
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REGULATION OF SECRETION 
 The  hypothalamic factor that inhibits prolactin secretion is the 
neurotransmitter dopamine which is secreted by arcuate nucleus by acting 
through D2 receptors. . 
 Thyrotropin-releasing hormone, stimulates  prolactin release, 
however prolactin is pitituary hormone which is  mainly under inhibitory 
control. 
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 The prolactin production is mainly controlled by estrogens , which 
directly stimulate prolactin production as well as acts by 
suppressing dopamine. It synthesis milk from the mammary gland by its 
enlargement (lactation), during pregnancy and also prepare for milk 
production. Lactation  starts when the levels of progesterone fall by the end 
of pregnancy and a suckling reflex starts. 
Vasoactive intestinal peptide and peptide histidine isoleucine are 
involved in the  regulation of prolactin secretion in humans. It has diurnal 
and ovulatory cycles. It  levels increase during REM sleep and in the early 
morning. High levels of estrogen and progesterone increase prolactin 
levels by 10- to 20-fold during pregnancy. 
In  vertebrates such as mice a ,similar actions with tissue specific 
effect is attained by a group  of prolactin-like proteins . 
  The sudden fall in level of estrogen and progesterone levels after 
the  delivery of baby will allow prolactin  to induce lactation in the women. 
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MECHANISM OF ACTION 
 The  prolactin expression is stimulated by cAMP present in decidual 
cells and in lymphocytes . 
 
It is mediated by an imperfect cAMP–responsive element and two 
CAAT/enhancer binding proteins (C/EBP)
. 
 
            Prolactin synthesis is increased by progesterone in the 
endometrium,where as it also decreases its level  in myometriumand breast 
glandular tissue.  
 
Pit-1 promoter in addition to the distal promoter expressed in breast 
and other tissues. 
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SUCKLING REFLEX  / MILK EJECTION REFLUX 
 
SUCKING  OF THE NIPPLE BY THE BABY 
 
ACTIVATES MECHANO RECEPTORS AROUND THE NIPPLE 
 
REFLUX FROM THESE RECEPTORS IS CARRIED BY NERVE 
FIBRES THROUGH SPINAL CORD 
 
IT IS CARRIED TO THE HYPOTHALAMUS 
 
THERE IS A CHANGE IN THE ELECTRICAL ACTIVITY OF 
NEURONS 
 
REGULATES THE PITUATARY GLAND TO SECRETE OXYTOCIN 
FROM POSTERIOR PITUATARY GLAND 
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Prolactin controls lactogenesis but not the milk-ejection reflex, this  
is mainly  done by oxytocin and the rise in prolactin level fills the breast 
with milk ,it thus prepares for the next feed. 
           It is found that level of prolactin rises during activities like exercise, 
sexual intercourse, breast examination, following minor surgical 
procedures or following epileptic seizures, may also increase due to 
physical  or emotional stress, following intake of high protein meal. 
 
OTHER FUNCTIONS OF PROLACTIN 
1. Prolactin cause the sexual refractory period. The  hormone  
counteracts the effect of dopamine, which is associated  to sexual 
arousal.  
2. Sex hormones level is regulated by change in level of prolactin  in 
women and testosterone in men which leads to spermatogenesis. 
3. It also  act as a weak gonadotropin, hence it suppresses  GnRH  
secretion. The  mechanism   is not  understood. 
4. Prolactin helps in the proliferation of oligodendrocyte precursor 
cells and its differentiation, which is involved in the synthesis of 
myelin. 
5. It affects the fetal lung surfactant synthesis , it also helps in building 
up of the immunity level in the fetus. 
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6. Fetal brain and maternal neural development is also controlled to 
many extent by the prolactin. The site of synthesis of prolactin is not 
only in the anterior pituitary, but is also produced in other sites like 
decidua, myometrium, breast, lymphocytes, leukocytes and prostate. 
 
ABNORMALITY IN PROLACTIN LEVEL 
 
PROLACTINOMAS :  Anterior pitituary tumour are associated with 
hyperprolactinemia. Prolactinomas may affects the hypothalamic – 
pituitary  gonadal axis by suppressing the secretion of GnRH 
PROLACTINOMA 
 
SUPPRESSES THE SECRETION OF GnRH SECRETION FROM 
HYPOTHALAMUS 
 
DECREASES THE SECRETION OF FSH AND LH 
 
DISRUPTS THE OVULATORY CYCLE 
 
AMENNORRHEA , INFERTILITY IN FEMALES 
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The other problems due to prolactinomas is mainly excessive lactation 
(galactorhea) and visual disturbances. 
 
STRUCTURE AND ISOFORMS 
 
 
 Chemically prolactin appears as posttranslational form with some 
chemical modifications like phosphorylation or glycosylation. Placental 
lactogen and growth factors has a structure similar to that of the prolactin. 
There is three disulfide bonds in its molecular structure.  
 The dominant form  of prolactin  is non-glycosylated form which is 
synthesized by pitituary gland. 
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SIZES OF PROLACTIN: 
   3 different sizes are seen 
1. Little prolactin - 
                      It is the predominant form. It has a structure with a single-
chain polypeptide of 198 amino acids. It has a molecular weight of about 
22-kDa.
]
 
2. Big prolactin 
                   Its weight is found to be more or less 48 kDa. It is usually 
formed as the product of interaction of several prolactin molecules. It has 
little biological activity. 
3. Big big prolactin 
                Its weight is about 150 kDa. It appears to have a low biological 
activity. In the early postpartum period there is increase in the level of 
larger ones. 
 
Serum prolactin level 
Units 
Nonpregnant 
Female 
First 
Trimester 
Second 
Trimester 
Third 
Trimester 
ng/mL 0 – 20 36 - 213 110 - 330 137 – 372 
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Serum prolactin level 
 
THE ROLE OF PROLACTIN IN THE PATHOGENESIS OF PRE 
ECLAMPSIA. 
1. Prolactin cause an increased response to vasopressor agent. 
2  There is an imbalance in angiogenesis and anti angiogenesis, this is 
leading on to pre eclampsia. 
3. Endothelial nitric oxide is one of the important factors which  controls 
the blood pressure, Prolactin causes elevation in the BP by decreasing 
the level of nitric oxide synthetase, which in turn leads on to decrease in 
the level of nitric oxide. 
4. It causes sodium and water retention of fluids and electrolytes affecting 
the osmoregulation. 
5. Elevation of arterial pressure during the pregnancy is directly controlled 
by the prolactin 
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AIMS OF STUDY 
• My study is about whether prolactin has a role in pathogenesis of 
preeclampsia and its severity, whether it can be used as a predictor 
of preeclampsia . 
• STUDY DESIGN - PROSPECTIVE STUDY. 
 
OBJECTIVES 
• To find if prolactin has a role in pathogenesis of preeclampsia. 
• To compare serum prolactin level  in all preeclampsia patients with 
normal healthy pregnant women 
• To correlate serum prolactin levels with severity of preeclampsia 
and its outcome.  
 
 
 
 
 
 
 
 
55 
 
MATERIALS AND METHODS 
 
TYPE OF STUDY : PROSPECTIVE OBSERVATIONAL STUDY. 
PERIOD OF STUDY : OCTOBER 2017-SEPTEMBER 2018. 
SAMPLE SIZE      :   100 preeclamptic patients  
100 normal pregnant women. 
 
PLACE OF STUDY : 
          Antenatal outpatient department, Antenatal ward and  Labor ward 
in the Dept of Obstetrics and Gynaecology, in Govt. Theni medical 
college. 
METHOD OF STUDY: 
● Careful history taking is done  as per the proforma. 
● This is followed by  Complete clinical examination  which is  done 
Under aseptic precaution, this is followed by  sampling , which is 
done  by venipuncture of  6ml of blood. The  blood is drawn out ,of 
which 4ml of blood will be used for routine investigation and TSH 
2ml of blood for serum prolactin which is done  by ELIZA clear 
method. The patients were  then followed up until delivery. 
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INCLUSION CRITERIA 
•  All pregnant patients with BP 140/90mmHg and urine albumin 1+ 
after 20 weeks of gestation. 
• All preeclamptic patients will be cases and all normal patients will 
be control.  
 
EXCLUSION CRITERIA 
• Chronic hypertension, 
• Type 1&2 diabetes mellitus. 
• Multiple pregnancy. 
• Thyroid disorders. 
• h/o galactorrhea. 
• H/o drug intake affect serum prolactin such as neuroleptics.  
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MATERIALS: 
 
SERUM PROLACTIN LEVEI. 
• Non-pregnant-     0-20 ng/ml 
• 1st trimester   -     36-213 ng/ml. 
• 2nd trimester  -     110-330 ng/ml. 
• 3rd trimester   -     137-372 ng/ml. 
 
BP MONITORING 
•   At booking visit. 
•   2nd  trimester -  every fortnight. 
•   3rd trimester  - every week. 
 
URINE ALBUMIN 
•    Grading of proteinuria. 
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DISCUSSION 
• The preeclampsia is mainly characterized by hypertension, edema 
and increased protein excretion. 
• Blood vessels in preeclamptic patients shows hyper response to 
pressor agents. 
• Normally Prolactin  was elevated in large amounts in pregnancy. 
• Prolactin is involved in osmoregulation that leads to sodium and 
water retention. 
• It causes increased vasoreactivity to angiotensin. Angiogenic 
process in preeclampsia is affected by high level of preeclampsia. 
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STATISTICAL ANALYSIS 
 The mean and standard deviation of the serum prolactin will be 
calculated and student 't’ test is used to compare mean. 
 
STATISTICAL ANALYSIS 
 Prolactin was taken  as the primary outcome variable. Presence or 
absence of Preeclampsia was considered as primary exposure variable. 
Different Age groups, parity, gestational age at which prolactin was taken 
were considered as other explanatory variables. Descriptive analysis of all 
the variables was done using mean, median and standard deviation for 
quantitative variables, frequency and percentage for categorical variables. 
The association between Preeclampsia and primary outcome variables was 
assessed by Independent Sample T-Test. Mean differences; standard 
deviation and p-value were calculated and presented. P value 0.001 was 
considered as statistically significant. 
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TABLE 1.Distribution of age in the study group 
Age No. of cases Percentage 
< 20  51 25.50 
21 – 25 75 37.50 
26 – 30 53 26.50 
> 30 21 10.50 
Total 200 100.00 
   
 
AGE DISTRIBUTION
51
75
53
21
25.50
37.50
26.50
10.50
0
10
20
30
40
50
60
70
80
< 20 21 - 25 26 - 30 > 30
No. of cases Percentage
 
 In study group 25.5%were in the age group less than 20 years and 
37.5%were in the age group 21to 25 years 26.5% in the age group between 
26 to30 years 10.50 %were in the age group between >30 years. 
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TABLE 2.Distribution of parity in study group 
 
Parity No. of cases Percentage 
Primi 98 49.00 
Multi 102 51.00 
Total 200 100.00 
 
 In this study 49% were primi 51% were multigravida 
 
PARITY DISTRIBUTION
49%
51%
Primi Multi
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TABLE3 : Gestational age at which prolactin level taken 
23
11.50
68
34.00
97
48.50
12
6.00
0
10
20
30
40
50
60
70
80
90
100
< 25 25 - 30 31 - 35 < 35
GA AT WHICH PROLACTIN TAKEN
No. of cases Percentage
 
 
GA at Which 
Prolactin taken 
No. of cases Percentage 
< 25 23 11.50 
25 - 30 68 34.00 
31 - 35 97 48.50 
< 35 12 6.00 
Total 200 100.00 
 
This table shows that, serum prolactin has taken maximum in the 
week of 31wk-35wk of gestation is about  48.5%, 
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TABLE 4  Pre Eclampsia 
 
Preeclampsia  No. of cases % 
Yes 91 45.50 
No 109 54.50 
Total 200 100.00 
 
 Among the study group 45.5% are  preeclampsia remaining  54.5% 
remain normotensive. 
 
PREECLAMPSIA DISTRIBUTION
46%
54%
Yes No
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TABLE 5. Non Severe& Severe preeclampsia 
PREECLAMPSIA No. of cases % 
Severe  44 22.00 
Non severe 47 23.50 
Total 91 45.50 
 
 Among the study group 54.5% remain normotensive ,23.50% are 
nonsevere pre eclampsia and 22% severe preeclampsia. 
 
44
47
42.5
43
43.5
44
44.5
45
45.5
46
46.5
47
Severe Non severe
PRE ECLAMPSIA - SEVERE / NON SEVERE
Severe Non severe
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TABLE 6;HELLP SYNDROME 
HELLP No. of cases % 
Yes 4 2.00 
No 196 98.00 
Total 200 100.00 
 
HELLP DISTRIBUTION
2%
98%
Yes No
 
Among the study group,2% of preeclamptic patients have HELLP 
SYNDROME. 
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TABLE 7;APECLAMPSIA 
AP Eclampsia No. of cases % 
Yes 8 4.00 
No 192 96.00 
Total 200 100.00 
 
 
AP ECLAMPSIA
4%
96%
Yes No
 
 
Among these study population,4% of preeclamptic patients are 
complicated with APECLAMPSIA. 
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TABLE 8;IUGR IN PREECLAMPSIA 
 
IUGR No. of cases % 
Yes 20 10.00 
No 180 90.00 
Total 200 100.00 
 
IUGR DISTRIBUTION
20
180
Yes No
 
 
Among preeclamptic patients,10% of them have IUGR. 
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TABLE 9:OUTCOME AND ITS COMPLICATION 
Outcome No. of cases % 
Abruption IUD 1 0.50 
Extreme Preterm 2 1.00 
IUD 11 5.50 
late Preterm  4 2.00 
Preterm 24 12.00 
Spontaneous 
expulsion 
1 0.50 
Term 27 13.50 
Total 70 35.00 
 
1
2
11
4
24
1
27
0
5
10
15
20
25
30
Abruption IUD Extreme
Preterm
IUD late Preterm Preterm Spontaneous
expulsion
Term
OUTCOME 
No. of cases
 
This table shows,preterm delivery has highest outcome  
of about 12%among the preeclamptic women,spontaneous expulsion 
and abruption placentae has least outcome of about 0.5% 
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TABLE10; Serum Prolactin Level in Study Population 
Prolactin ng/ml vspreclampsia 
  Yes No 
< 200(91) 11 80 
201 - 300(58) 29 29 
> 300(51) 51 0 
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Preeclampsia vs Prolactin 
Preeclampsia Mean SD p' value 
Yes(91) 309.99 81.556   
No(109) 174.17 52.684 <0.001 
 
309.99
174.17
0
50
100
150
200
250
300
350
Yes(91) No(109)
PRE ECLAMPSIA VS PROLACTIN
Mean
 
The statistically significant difference between the mean serum 
prolactin level of the preeclamptic and normal patients denotes a 
significant association . 
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TABLE11; Prolactin Level in Nonsevere/Severe  Preeclampsia 
Prolactin ng/ml vs Severe 
  Yes No 
< 200(91) 0 91 
201 - 300(58) 3 55 
> 300(51) 42 9 
This diagram shows ,mean value of prolactin level in nonsevere is 
about 245.66ng/ml and in severe is about 370.21ng/ml. 
Preeclampsia Severity vs Prolactin 
Preeclampsia Mean SD p' value 
Non Severe(44) 245.66 69   
Severe(47) 370.21 29.978 <0.001 
 
This table shows statistically significant association between prolactin 
level with nonsevere/ severe 
 
245.66
370.21
0
50
100
150
200
250
300
350
400
Non Severe(44) Severe(47)
PRE ECLAMPSIA -  SEVERITY VS PROLACTIN
Non Severe(44) Severe(47)
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TABLE12; Prolactin in HELLP Syndrome 
Prolactin ng/ml vs HELLP  
  Yes Partial No 
< 200(91) 0 0 91 
201 - 300(58) 0 0 58 
> 300(51) 3 1 47 
  
387.25
232.88
0
50
100
150
200
250
300
350
400
Yes(4) No(196)
HELLP VS PROLACTIN
Yes(4) No(196)
 
Prolactin vs HELLP 
HELLP Mean SD p' value 
Yes(4) 387.25 23.768   
No(196) 232.88 93.865 0.001 
This shows significant association of serum prolactin level with 
HELLP syndrome. 
This table shows that , among 4 patients of HELLP ,the mean 
level of prolactin is more than 380ng/ml. 
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TABLE13; Prolactin Level in ApEclampsia 
Prolactin ng/ml vs AP Eclampsia 
  Yes No 
< 200(91) 0 91 
201 - 300(58) 0 58 
> 300(51) 8 43 
 
Prolactin vs AP Eclampsia 
AP Eclampsia Mean SD p' value 
Yes(8) 383.13 15.923   
No(192) 229.84 92.407 <0.001 
 
383.13
229.84
0
50
100
150
200
250
300
350
400
Yes(8) No(192)
AP ECLAMPSIA VS PROLACTIN
Mean
 
This table shows that, 8 AP Eclamptic patients have  serum 
prolactin level more than 300ng/ml,cut off value of about 
383ng/ml.This denotes statistically difference between mean serum 
prolactin level and APEclampsia.  
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TABLE 14; Serum Prolactin in IUGR 
370.15
221.06
0
50
100
150
200
250
300
350
400
Yes(20) No(180)
IUGR VS PROLACTIN
Yes(20) No(180)
 
Prolactin ng/ml vs IUGR 
  Yes No 
< 200(91) 0 91 
201 - 300(58) 3 55 
> 300(51) 17 34 
 
Prolactin vs IUGR 
IUGR Mean SD p' value 
Yes(20) 370.15 47.068   
No(180) 221.06 87.517 <0.001 
 
This table shows that ,the level of prolactin in IUGR patients cut off 
value about 370 ng/ml. 
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TABLE 15; Prolactin vs Outcome 
Prolactin ng/ml vs Outcome 
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< 200(91) 7 0 0 0 0 0 0 84 
201 - 300(58) 10 1 3 0 0 0 0 44 
> 300(51) 10 3 21 1 2 11 1 2 
 
This shows, prolactin level was high in preterm delivery which is more 
than 300ng/ml 
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Outcome vs Prolactin 
Outcome  Mean SD p' value 
Abruption IUD 398.0 0.00 
<0.001 
Extreme Preterm 365.0 21.21 
IUD 375.4 23.93 
late Preterm  365.3 43.71 
Preterm 360.5 45.73 
Spontaneous expulsion 361.0 0.00 
Term 274.1 94.43 
Nil 185.1 56.90 
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TABLE 16 
Prolactin level Hypertensive Normotensive Total 
Prolactin>300ng/
ml 
51(a) 0(b) 51(a+b) 
Prolactin<300ng/
ml 
40(c) 109(d) 149(c+d) 
Total 91(a+c) 109(b+d) 200 
 
Sensitivity  :  a / a+c x 100 
                       51/91 x 100 
                       56.04% 
 specificity : d/ c+d x 100 
                     109/109 X 100 
                    100% 
positive predictive value : a/ a+b x 100 
                                         51/51 x100 
                                          100% 
 
Negative predictive value : c/ c+d x 100 
                                            40/149 x 100 
                                             26.9% 
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RESULTS 
In this study, majority of the women about 37.5% was in the age 
group between 21 and 25 years.51% were multigravida,49% were 
primigravida.45.5% of women are preeclampsia out of  which 22%were 
developed nonsevere preeclampsia and 23.5% were developed severe 
preeclampsia. The complications like HELLP were about 4%,AP 
Eclampsia about 8% and IUGR 10%.The most common outcome of 
pregnancy was preterm delivery about 12%.It is found that mean prolactin 
level in preeclamptic women was 309.9 and non-preeclamptic women was 
174.12 taken during mean gestational age between 31-35weeks.In which 
mean concentration of prolactin level in non-severe preeclampsia was 
245.66and in severe preeclampsia was 309.9.The complication of 
preeclampsia like HELLP,AP Eclampsia occurred at mean level of 
prolactin was 383.13.Based upon the statistical analysis sensitivity of the 
test is 56.04% and specificity is 100%,positive predictive value is 100% 
and negative predictive value is 26.9%. Hence p value is <o.oo1 ,which is 
statistically significant.    
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SUMMARY 
This prospective observational study was done at Theni Medical 
College and Hospital. After getting consent from the patients serum 
prolactin was taken from 200 women out of which 100 woman are 
normal,100 woman are preeclamptic women after 20 week of 
gestation.100 preeclamptic women came for follow up till delivery.
 Proper history taking, clinical examination was done, BP and urine 
albumin was checked in every visit. 
         In my study, out of 91 preeclamptic women,51  patients show mean 
prolactin level more than 300ng/ml. There is a significant association 
between mean prolactin level and complications of preeclampsia like 
HELLP, APeclampsia, IUGR and adverse perinatal outcome(preterm).It is 
found that raised mean concentration of serum prolactin level associated 
with hypertension in pregnancy and its complications.  
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CONCLUSION 
 
This study revealed increased level of prolactin was  associated with 
preeclampsia when compared to healthy women and more with 
complications. Still large number of study is needed to conclude. Thus 
prolactin can be used as a reliable marker for preeclampsia.  
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ABBREVIATIONS 
 
PRL   - Prolactin  
UPRL -  Urinary Prolactin 
SPE  - Severe Pre Eclampsia 
MPE   - Mild Pre Eclampsia 
VEGF  - Vascular Endothelial Growth Factor  
PLGF  - Placental Like Growth Factor 
CO  - Cardiac Output  
PVR  - Pulmonary Vascular Resistance 
GA   - Gestational Age  
BP  - Blood pressure 
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PROFORMA 
NAME     AGE   IP NO 
PHONE NUMBER 
ADDRESS 
HUSBANDS NAME 
OCCUPATION 
QUALIFICATION 
SOCIOECONOMIC STATUS 
OBSTETRIC HISTORY 
      PARITY 
      LMP        EDD 
GA BY LMP 
GA BY USG 
MENSTRUAL HISTORY        
MARITAL HISTORY 
PAST HISTORY 
   1.Diabetes 
   2.Hypertension 
   3.Heart disease 
   4.Thyroid disorders 
   5.Bronchial asthma 
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   6.Liver/renal disease 
   7.Drug intake. 
   8.Epilepsy.  
GENERAL EXAMINATION 
HEIGHT 
WEIGHT 
PALLOR 
PEDAL EDEMA 
PULSE  
BP 
CVS 
RS 
CNS 
PER ABDOMEN 
THYROID 
BLOOD INVESTIGATIONS  
RFT    LFT    TSH 
URINE ALBUMIN 
SERUM PROLACTIN.  
OUTCOME. 
 
 
1 
 
 
 
1 
Sl.No. Name Age Parity 
GA at 
Which 
Prolactin 
taken 
Prolactin 
ng/ml 
Preeclampsia  Non 
severe 
Severe 
HE 
LLP 
AP Eclam 
psia 
IUGR Outcome 
Yes No 
1 Thavamani 23 G2 A1 30 + 2  220  -  - - - - Term 
2 Gayathri 21 G2 P1 L1 28 + 4  115  -  - - - - Term 
3 Sarikala 20 Primi 33 + 2  215 - - - - - - - - 
4 Kokila 22 Primi 28 + 5  122 - - - - - - - Term 
5 Kamatchi 19 G3 A2 31 + 2  382  - -  - -  Preterm 
6 Mariyammal 19 G2 P1 L1 29 + 1  218 - - - - - - - - 
7 Devi 35 G2 P1 L0 35 + 1  390  - -  -   Late Preterm 
8 Archana 24 Primi 32 + 1  220  -  - - - - Term 
9 Benazibegum 28 G2 P1 L1 28 + 1  340  - -  - - - IUD 
10 Revathy 20 G3 P2 L2 32 + 4  118 - - - - - - - - 
11 Anitha 21 Primi 27 + 2  240  -  - - - - Term 
12 Malathy 22 G2 P1 L0 33 189  -  - - - - - 
13 Maheswari 19 Primi 34 + 2  220 - - - - - - - - 
14 Savithri 32 Primi 32 + 6  300  - -  - -  Late Preterm 
15 Saraswathy 25 G2 P1 L1 27 + 2  118 - - - - - - - - 
 
2 
16 Akila 27 
G2 P1 L1 
A1 
32 + 1  198  -  - - - - - 
17 Kamatchiammal 21 
G2 P1 L1 
A2 
34 + 3  390  - -  Partial -  Late Preterm 
18 Pandiyammal 20 G2 A1 30 + 2  180 - - - - - - - - 
19 Sasi 23 Primi 33 + 1  218 - - - - - - - - 
20 Kokila 26 G3 P2 L2 36 + 1  300 - - - - - - - - 
21 Vimala 22 Primi 34 + 2  313  -  - - - - Term 
22 Maheswari 25 Primi 32 + 3  390  - -  - - - Preterm 
23 Zareena Begum 19 Primi 33 + 2  380  - -  - -  Term 
24 Venkateshwari 23 G2 A1 27 + 1  118 - - - - - - - - 
25 Vijayalakshmi 28 Primi 36 + 1  300 - - - - - - - - 
26 Vimala 18 Primi 32 + 4  220  -  - - -  Preterm 
27 Autrika 19 Primi 29 + 3  118 - - - - - - - - 
28 Chandra 19 Primi 30 + 1  184 - -  - - - - - 
29 Devika 28 G3 P2 L2 34 + 2  299 - - - - - - - - 
30 Roselin 19 Primi 29 + 2  153 -  - - - - - - 
31 Devi 30 
G5 P2 L2 
A2 
33 + 5  384  - -  - - - Preterm 
32 Aushiya 18 Primi 27 + 3  118 - - - - - - - - 
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33 Vidhya 21 G3 A2 31 + 4  221  -  - - - - - 
34 Pandeeshwari 26 G2 P1 L1 36 + 2  380  - -  - -  Term 
35 Velammal 24 Primi 33 + 1  284  -  - - - - - 
36 Mudiyammal 21 Primi 30 + 2  210 -  - - - - - - 
37 Ramya 22 G2 P1 4 28 + 3  190 -  - - - - - - 
38 Munieshwari 19 Primi 27 + 2  118 -  - - - - - - 
39 Vani 18 G2 A1 34 + 3  270  -  - - - - Term 
40 Sridevi 31 
G4 P1 L1 
A2 
28 + 5  380  - -  -  - IUD 
41 Vanaja 35 G2 P1 L0 34 + 2  398  - - - -  - 
Abruption 
IUD 
42 Visalatchi 23 Primi 26 + 1  170 -  - - - - - - 
43 Vanitha 18 Primi 31 115     - - - - - 
44 Selvi 24 G2 P1 L1 34 + 2  250 -  - - - - - - 
45 Pandriselvi 26 Primi 30 + 2  118 -  - - - - - - 
46 Vijaya 28 
G3 P1 L1 
A2 
32 + 1  254 -  - - - - - - 
47 Vedamani 30 
G5 P2 L2 
A2 
35 + 2  284  -  - - - - Term 
48 Muthumani 18 Primi 28 + 2  112 -  - - - - - - 
49 Kowsalya 19 Primi 32 + 4  375  - -  - -  Term 
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50 Amutha 21 Primi 31 + 5  210  -  - - - - - 
51 Rajina Beevi 20 G3 A2 28 + 3  184 -  - - - - - - 
52 Vigneshwari 21 Primi 29 + 1  115 -  - - - - - - 
53 Soundarya 25 
G4 P1 L1 
A2 
23 + 2  130 -  - - - - - - 
54 Sabeena begam 26 
G3 P1 L1 
A4 
31 + 3  284  - -  - - - Preterm  
55 Pandiyammal 34 
G6 P2 L1 
A4 
34 + 2  380  - - -  - - IUD 
56 Kokila 18 Primi 31 + 2  118 -  - - - - - - 
57 Kavitha 19 Primi 33 + 1  121  -  - - - - - 
58 Rukmani 25 G2 P1 L1 29 + 2  186 -  - - - - - - 
59 Mala 26 
G3 P1 L1 
A1 
35 + 5  218  -  - - - - - 
60 Manibharathi 29 
G3 P1 L1 
A1 
36 + 3  284  - - - - - - - 
61 Andal 18 Primi 28 + 4  382  - -  -  - IUD 
62 Chitra 20 Primi 31 + 3  184 -  - - - - - - 
63 Pandimeena 20 Primi 22 + 3  282 -  - - - - - - 
64 Vishwa 22 G2 P1 L1 24 + 4  382  - -  - -  Preterm 
65 Ashwini 23 G3 A2 26 + 5  184 -  - - - - - - 
66 Devika 34 G6 P1 L1 31 + 2  218 -  - - - - - - 
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A5 
67 Eswari 31 G2 P1 L1 34 + 3  320ng  -  - - - - - 
68 Mariyammal 18 Primi 36 + 1  219ng  -  - - - - Term 
69 Munieshwari 22 G3 A2 27 + 2  117ng -  - - - - - - 
70 Pandiyammal 25 Primi 32 + 3  240ng  -  - - - - - 
71 Anitha 26 
G3 P1 L1 
A1 
28 + 1  340ng  - -  - - - Preterm 
72 Bhoomeshwari 27 
G5 P1 L1 
A3 
30 + 2  280ng  -  - - - - Term 
73 Vijaya 20 Primi 31 + 3  118ng -  - - - - - Term 
74 Lakshmi 22 Primi 35 + 2  381ng  - -  - -  late Preterm  
75 Lavanya 25 G2 A1 29 + 3  121ng -  - - - - - - 
76 Meenakshi 26 
G3 P1 L1 
A1 
33 + 2  300ng  -  - - - - Term 
77 Nirmala 28 G2 P1 L1 31 + 2  180 -  - - - - - - 
78 Kokila 29 G4 P3 L3 32 + 3  284 -  - - - - - - 
79 Gomathy 31 
G3 P1 L1 
A1 
36 + 7  389  -  - - - - Term 
80 Vasanthi 32 
G4 P1 L1 
A2 
33 + 1  298 -  - - - - - - 
81 Nandhini 30 Primi 22 + 3  390  - -  - -  Preterm 
82 Chandralekha 28 G2 A1 31 + 2  284  -  - - - - - 
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83 Malini 27 
G3 P1 L1 
A1 
37 + 1  210 -  - - - - - - 
84 Kavitha 26 Primi 30 + 3  184  -  - - - - Term 
85 Banumathy 25 Primi 28 + 4  375  - -  - - - IUD 
86 Sonia 22 G2 A1 21 + 3  220 -  - - - - - - 
87 Sivapriya 23 Primi 24 + 2  182 -  - - - - - - 
88 Indumathy 29 G2 P1 L1 30 + 3  198  -  - - - - - 
89 Indhra 32 Primi 31 + 4  272  -  - - - - - 
90 Pandiyammal 31 
G3 P1 L1 
A1 
34 + 3  118 -  - - - - - - 
91 Saranya 28 G2 P1 L1 27 + 3  184 -  - - - - - - 
92 Rekha 26 Primi 26 + 4  210  -  - - - - - 
93 Yamuna 25 G3 A2 21 + 5  300  - -  - -  Preterm 
94 Ambika 23 G2 A4 25 + 4  312  - -  - - - Preterm 
95 Devika 24 G2 P1 L1 31 + 2  292  -  - - - - - 
96 Banumathy 18 Primi 22 + 2  340  - -  - - - IUD 
97 Selvi 21 Primi 28 + 3  118 -  - - - - - - 
98 Lakshmipriya 22 G2 A1 33 + 1  240 -  - - - - - - 
99 Mahalakshmi 35 
G6 P2 L1 
A3 
34 + 1  400  - -  -   Preterm 
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100 Saranya 34 G2 P1 L1 31 + 2  312  -  - - - - - 
101 Devipriya 25 Primi 30 + 1  184 -  - - - - - - 
102 Sridevi 26 G2 A1 21 + 5  215  -  - - - - - 
103 Pandipriya 21 
G3 P1 L1 
A1 
31 + 2  350  - -  - - - Preterm 
104 Inbarathi 22 Primi 30 + 1  118 -  - - - - - - 
105 Revathy 18 Primi 29 + 1  210 -  - - - - - - 
106 Priyadharshini 19 Primi 32 + 1  300  -  - - - - Term 
107 Ashwini 20 Primi 31 + 5  188 -  - - - - - - 
108 Pandimurugeshwari 22 G2 A1 22 + 3  398  - -  - -  IUD 
109 Muthumeena 22 Primi 24 + 3  118 -  - - - - - - 
110 Leelavathy 23 Primi 31 + 5  125 -  - - - - - - 
111 Skathipriya 25 G2 A1 35 + 3  218 -  - - - - - - 
112 Maheshwari 26 G2 P1 L1 32 + 1  380  -  - - - - Term 
113 Subha 27 G2 P1 L1 33 + 2  382  - -  - - - Preterm 
114 Sathya 28 
G3 P1 L1 
A1 
35 + 3  270  -  - - - - - 
115 Chinnapoonu 29 
G4 P2 L1 
A1 
37 + 2  255 -  - - - - - - 
116 Sundrammal 31 Primi 21 + 3  174 -  - - - - - - 
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117 Suganya 32 G2 P1 L1 24 + 4  184 -  - - - - - - 
118 Vijayapriya 28 G2 P1 L1 27 + 3  115 -  - - - - - - 
119 Komathy 25 Primi 31 + 4  180 -  - - - - - - 
120 Nirmaladevi 18 Primi 32 + 5  172 -  - - - - - - 
121 Marieshwari 31 G3 P2 L2 36 + 1  374  - -  - - - Term 
122 Elakiya 19 Primi 32 + 3  184 -  - - - - - - 
123 Priya 23 Primi 33 + 4  187 -  - - - - - - 
124 Sangeetha 24 Primi 26 + 1  167 -  - - - - - - 
125 Nandhini 26 Primi 27 + 2  350  - -  -  - 
Extreme 
Preterm 
126 Fathima 27 G2 A1 31 + 3  415  - -  - -  Preterm 
127 Thangamani 19 Primi 34 + 1  128 -  - - - - - - 
128 Kamatchi 20 Primi 35 + 2  134 -  - - - - - - 
129 Komala 38 
G4 P2 L1 
A1 
28 + 2  212  -  - - - - - 
130 Alandhinipriya 19 Primi 30 + 2  118 -  - - - - - - 
131 Punitha 18 Primi 32 + 3  151 -  - - - - - - 
132 Radha 22 Primi 27 + 2  167 -  - - - - - - 
133 Subathra 24 G2 P1 L1 31 + 3  415  - -  - -  Preterm 
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134 Hemalatha 24 Primi 28 + 2  188 -  - - - - - - 
135 Yasmin 25 Primi 33 + 5  218  -  - - - - - 
136 Aryamal 38 
G3 P1 L1 
A2 
35 + 2  124 -  - - - - - - 
137 Sudha 19 Primi 22 + 3  343  - -  - - - Preterm 
138 Kannagi 18 G2 A1 24 + 6  210 -  - - - - - - 
139 Seetha 20 G2 A1 31 + 4  118 -  - - - - - - 
140 Dharani 21 Primi 32 + 4  175 -  - - - - - - 
141 Rupa 22 Primi 33 + 2  184 -  - - - - - - 
142 Vaishnavi 23 Primi 21 + 1  115 -  - - - - - - 
143 Jayanthi 24 G3 A2 31 + 3  110 -  - - - - - - 
144 Usha 24 G2 P1 L1 34 + 2  117 -  - - - - - - 
145 Ruthra 19 Primi 23 + 5  182 -  - - - - - - 
146 Sharmila 18 Primi 24 + 2  190 -  - - - - - - 
147 Alphone 26 
G3 P1 L1 
A1 
28 + 1  342  - -  - - - Preterm 
148 Geetha 27 G2 P1 L1 30 + 2  184 -  - - - - - - 
149 Karpagam 28 G2 A1 31 + 3  186 -  - - - - - - 
150 Dhivya 30 G2 A1 35 + 2  147 -  - - - - - - 
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151 Alamelu 31 
G3 P1 L1 
A1 
36 + 1  247 -  - - - - - - 
152 Alayammal 32 G2 P1 L1 32 + 1  284 -  - - - - - - 
153 Janaki 28 G2 P1 L1 31 + 5  380  - -  - - - 
Extreme 
Preterm 
154 Pavithra 25 Primi 30 171 -  - - - - - - 
155 Krishnaveni 26 Primi 31 + 1  180  -  - - - - - 
156 Bhuvaneshwari 24 Primi 21 + 4  174 -  - - - - - - 
157 Rajalakshmi 21 Primi 25 + 2  181 -  - - - - - - 
158 Shanthi 24 G2 P1 L1 27 + 8  134 -  - - - - - - 
159 Mohana 22 Primi 31 + 1  212 -  - - - - - - 
160 Saiyani 18 Primi 32 + 3  230 -  - - - - - - 
161 Selvapriya 20 Primi 33 + 4  254  -  - - - - - 
162 Aruna 18 Primi 21 + 3  184 -  - - - - - - 
163 Preethi 24 Primi 31 + 1  418  - -   - - IUD 
164 Kayalvizhi 26 G2 A1 32 + 3  220 -  - - - - - - 
165 Jyothi 27 
G3 P1 L1 
A1 
33 + 1  184 -  - - - - - - 
166 Kanimozhi 30 
G5 P2 L1 
A2 
34 + 5  380  - -  - - - Preterm 
167 Narmadha 28 G2 P1 L1 28 + 3  115 -  - - - - - - 
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168 Poogulai 27 Primi 22 + 4  125 -  - - - - - - 
169 Vishnupriya 19 Primi 21 + 3  130 -  - - - - - - 
170 Akila 20 Primi 31 + 1  140 -  - - - - - - 
171 Radha 23 Primi 30 + 1  272 -  - - - - - - 
172 Stella 20 Primi 26 + 2  350  - -  - - - Preterm 
173 Chellammal 21 Primi 33 + 3  380  -  - - - - Term 
174 Manimozhi 25 G2 P1 L1 21 + 6  118 - - - - - - - - 
175 Karthikeyani 26 Primi 23 + 6  375  - -  -   IUD 
176 Haripriya 27 
G3 P1 L1 
A1 
31 + 2  118 -  - - - - - - 
177 Sindhu 28 
G4 P1 L1 
A2 
32 + 1  131 -  - - - - - - 
178 Swetha 30 
G3 P1 L1 
A1 
33 + 1  141 -  - - - - - - 
179 Vasumathi 32 G2 P1 L1 28 + 2  181 -  - - - - - - 
180 Gnanamathi 19 Primi 30 + 1  200 -  - - - - - - 
181 Poornima 18 Primi 21 + 5  211 -  - - - - - - 
182 Punithamani 22 Primi 22 + 8  118 -  - - - - - - 
183 Jayalakshmi 23 Primi 24 + 5  361  - -   - - 
Spontaneous 
expulsion 
184 Hema 25 Primi 26 + 1  390  - -  - (PRES) - IUD 
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185 Mariya 26 Primi 28 + 3  115 -  - - - - - - 
186 Kalpana 30 G2 P1 L1 30 + 2  131 -  - - - - - - 
187 Ruby 18 Primi 33 + 1  148  -  - - - - Term 
188 Deepa 25 Primi 34 + 2  184  -  - - - - Term 
189 Jennija 22 G2 A1 35 + 1  391  -  - - - - Term 
190 Vinodhini 23 G3 A2 31 + 4  171  -  - - - - Term 
191 Pushpa 24 G2 P1 L1 37 + 1  118 -  - - - - - - 
192 Saiyamitha 27 G3 P2 L2 32 + 1  400  - -  - -  Preterm 
193 Shymala 28 Primi 33 + 1  380  - -  - - - Preterm 
194 Manimozhi 29 G2 A1 25 + 6  340  - -  - -  Preterm 
195 Nabeesha 18 Primi 25 + 6  351  - -  - - - IUD 
196 Gayathri devi 20 Primi 27 + 1  381  - -  - - - Preterm 
197 Raka Sri 21 Primi 28 + 1  284  -  - - - - Term 
198 Reena 22 G2 A1 30 + 1  380  - -  - - - Term 
199 Kavitha 21 G2 P1 L1 34 + 2 281 -  - - - - - - 
200 Vanisri 22 G3 A1 31 + 3 390  - -  - -  Preterm 
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